Videos

A discussion on decision factors for switching to and deciding upon a second-line therapy, and an overview of the phase 3 REACH2 study with ruxolitinib for glucocorticoid-refractory acute graft-vs-host disease (GVHD).

Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.

Clinical updates from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Insight regarding the assessment of minimal residual disease in patients with multiple myeloma and using testing results to aid in treatment selection.

Key opinion leaders discuss treatment goals for frontline therapy in patients with acute graft-vs-host disease.

Rationale regarding the use of BCMA-targeted CAR T-cell therapy in relapsed/refractory multiple myeloma.

Expert physicians discuss the role and efficacy of JAK inhibitors in steroid-refractory graft-vs-host disease (GVHD).

Considerations for adding daratumumab to the combination of lenalidomide and dexamethasone to treat transplant-ineligible newly diagnosed multiple myeloma based on updated efficacy data from the phase 3 MAIA trial.

Mayo Clinic’s Rafael Fonseca, MD, comments on the benefits of newer therapies that are now available for patients with newly diagnosed transplant-ineligible multiple myeloma.

A discussion on the role on Janus kinase signaling in the pathogenesis of acute and chronic graft-vs-host disease (GVHD).

Deepu Madduri, MD, provides an overview of the treatment landscape for patients with triple-class refractory multiple myeloma.

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

Deepu Madduri, MD, discusses how chimeric antigen receptor T-cell therapy is used for patients with multiple myeloma.

Caron Jacobson, MD, discusses the survival and response data for axicabtagene ciloleucel from the phase 1/2 ZUMA-1 trial.

Saad Usmani, MD, speculates on the current progress in treating multiple myeloma, while providing a glimpse into the future of cutting-edge treatments.

Saad Usmani, MD, reflects on the impact the coronavirus pandemic has had on his practice and the treatment of patients with multiple myeloma overall.

The MAIA & PEGASUS Trial and Managing Patients Receiving DRd

Saad Usmani, MD, analyzes the efficacy and safety data results from the phase 3 MAIA study.

Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma and describes the patient’s current prognosis.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

Preetesh Jain, MD, PhD, discusses the efficacy and predictors of response with ibrutinib and rituximab in combination as treatment of patients with previously untreated mantle cell lymphoma.

Roman Perez-Soler, MD, discusses the use of MET inhibitors as treatment of patients with lung cancer and the evolving role of targeted therapy in the lung cancer setting.

Experts in genitourinary oncology share their excitement for promising emerging agents and combination therapies for advanced prostate cancer in the coming years.

Mary-Ellen Taplin, MD, presents data from the phase 2 TRITON2 trial of rucaparib in metastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, presents data from the phase 3 PROfound trial of olaparib in metastatic castration-resistant prostate cancer.

Patrick G. Pilié, MD, presents data from the phase 3 CARD trial of cabazitaxel in metastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, shares her method for selecting and dosing chemotherapy for metastatic castration-resistant prostate cancer.